Tengion Overview
Tengion General Information
Description
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Tengion Stock Performance
(As of Tuesday closing)
| Stock Price |
Previous Close |
52 wk Range |
Market Cap |
Shares |
Average Volume |
EPS |
|
|
|
|
|
132K |
|
Tengion Financials Summary
In Thousands,
USD
|
TTM
30-Sep-2014
|
FY 2013
31-Dec-2013
|
FY 2012
31-Dec-2012
|
FY 2011
31-Dec-2011
|
| EV |
21,804 |
2,588 |
6,175 |
(2,938) |
| Revenue |
0 |
0 |
0 |
0 |
| EBITDA |
(56,419) |
(11,085) |
(13,543) |
(15,124) |
| Net Income |
(64,426) |
(18,927) |
(16,929) |
(19,061) |
| Total Assets |
9,621 |
25,724 |
12,435 |
17,817 |
| Total Debt |
34,122 |
26,952 |
11,269 |
4,987 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Tengion Valuation & Funding
| Deal Type |
Date |
Amount |
Valuation/
EBITDA |
Post-Val |
Status |
Debt |
This information is available in the PitchBook Platform. To explore Tengion‘s full profile, request access.
Request a free trial
Tengion Competitors (24)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| ViaCyte |
Venture Capital-Backed |
San Diego, CA |
00 |
00000 |
00000000000 |
00000 |
| 000 0000000000000 |
Venture Capital-Backed |
Seattle, WA |
00 |
000.00 |
0000000000 0 |
000.00 |
| 00000000 |
Venture Capital-Backed |
South San Francisco, CA |
|
0000 |
00000000000 |
0000 |
| 00000 0000000000 |
Accelerator/Incubator Backed |
Phoenix, AZ |
|
0000 |
000000000000 |
0000 |
| 000000 0000000 |
Accelerator/Incubator Backed |
Marietta, GA |
|
|
000000000000 |
|
Tengion Executive Team (12)
| Name |
Title |
Board Seat |
Contact Info |
| A. Davis MD |
Chief Financial Officer, Finance & Chief Accounting Officer, Accounting |
|
|
| John Miclot |
Chief Executive Officer & Board Member |
|
|
| Timothy Bertram Ph.D |
Chief Scientific Officer & President |
|
|
9 Former Executives
Tengion Board Members (11)
To view Tengion‘s full board member team, request access >>
| Name |
Representing |
Role |
Since |
| 0000-00000 000000000 00.0 |
Self |
Board Member |
000 0000
|
| 00000 000000 |
Tengion |
Chairman & Board Member |
000 0000
|
| 00000 00000000 00 |
Self |
Board Member |
000 0000
|
| 0000 000000 |
Self |
Chief Executive Officer & Board Member |
000 0000
|
| 0000000 00000 00 |
Self |
Board Member |
000 0000
|
6 Former Board Members